Amgen Oncology is testing the investigational drug tarlatamab (AMG 757) to see if it can help patients with either of two kinds of neuroendocrine cancer: small cell lung cancer (SCLC) or neuroendocrine prostate cancer (NEPC).
Move your cursor to either side of the page to learn more about tarlatamab clinical studies.
Underlined terms can be clicked for definition.
DeLLphi-304 (Phase 3) Clinical Study
DeLLpro-300 (Phase 1B) Clinical Study